KPV for Ulcerative Colitis: 8-Week Update

For FormBlends KPV, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.

I’m writing this mid-protocol, not after. That’s deliberate. The peptide community has plenty of “here’s my final result” posts. What it doesn’t have is granular documentation of what the first eight weeks of a KPV protocol actually look like when you’re living inside it, tracking labs, logging symptoms daily, and still not sure whether the thing is working or whether your disease just decided to calm down on its own.

The compliance frame, because it matters. KPV is the C-terminal tripeptide fragment of alpha-melanocyte stimulating hormone (alpha-MSH). It is a research-stage peptide with no FDA approval for any human indication. In the United States, it’s accessed through 503A compounding pharmacies via individual patient prescriptions based on prescriber clinical judgment. The FDA placed KPV on the 503A bulks list under review in 2023. Nothing in this post is medical advice.

The starting line

I’m 41. Diagnosed with ulcerative colitis at 36, moderate, mostly left-sided, the kind that flares in cycles and makes you rearrange your entire life around bathroom proximity. Standard treatment: mesalamine 4.8 grams daily, with periodic prednisone bursts when things go sideways. The mesalamine works. It has never worked enough. I’d get better, never quite reach sustained remission, and then the next flare would roll in like weather.

The flare that led to this protocol had been smoldering for about three months. Not catastrophic. Just persistent enough to grind you down. My gastroenterologist, who is conservative but not closed-minded, suggested I work with a functional medicine doctor on adjunctive options while she continued managing primary treatment through her office.

That’s how I ended up in a telehealth consult with Dr. Rachel Stein out of Portland. She pulled up my calprotectin (612), looked at my CRP (14), and said something I appreciated: “There’s a plausible mechanism here, the animal data is interesting, and we have almost no controlled human data. If you want to try it, we run it like a proper trial with labs at four and eight weeks, and we don’t pretend we know more than we know.”

She walked me through the science. KPV has been studied in vitro and in animal models for inflammatory bowel disease, where its mechanism appears to involve melanocortin receptor signaling that downregulates inflammatory pathways in the gut. The human evidence? Very limited. No large randomized controlled trial. Compounded use is off-label and exploratory. We agreed on an 8-week initial course with strict before-and-after evaluation and all standard treatment continuing in parallel.

The protocol

• KPV: 500 mcg subcutaneous twice daily
• Site: abdomen, rotating quadrants
• Concurrent: mesalamine continued at full dose, no new supplements, no diet changes beyond what I was already doing
• Baseline labs: CBC, CRP, fecal calprotectin, comprehensive metabolic panel
• Repeat labs: at 4 and 8 weeks
• Symptom log: daily capture of stool frequency, urgency, blood, abdominal pain rating (1-10 scale)

Weeks 1 and 2: The Nothing Phase

If you’re expecting a peptide to announce itself, KPV doesn’t. The first two weeks produced zero obvious symptom changes. Stool frequency stayed elevated compared to my well-controlled baseline. Urgency was unchanged. Small amounts of visible blood were still present most days.

The injections were uneventful. Brief mild warmth at the site lasting less than an hour. No nausea, no headaches, no systemic side effects worth noting.

I’ll be honest: by day 10, I was mentally filing this under “expensive placebo.” Dr. Stein reminded me that the published mechanism would predict a gradual reduction in inflammatory signaling over weeks, not days, and that calprotectin would likely be the most sensitive early indicator. “If nothing has changed at four weeks, we’ll talk about stopping,” she said. Fair enough.

Weeks 3 and 4: The first real signal

This is where things shifted. Stool frequency started dropping from a baseline of 6 to 8 per day toward 4 to 5. Urgency decreased meaningfully (the difference between “I need a bathroom in 30 seconds” and “I need a bathroom in 10 minutes” is, if you have UC, enormous). Blood became intermittent rather than daily.

The week-4 labs confirmed what the symptom log was suggesting. Fecal calprotectin dropped from 612 to 384. CRP fell from 14 to 7. Both markers moved in the right direction by a meaningful magnitude.

Abdominal pain rating decreased from an average of 4 out of 10 to about 2.

Here’s the thing about a gradual response curve: it doesn’t feel dramatic while it’s happening. It’s more like realizing you haven’t sprinted to the bathroom in three days, and that realization arriving almost casually.

Weeks 5 and 6: Slower gains, same direction

Improvement continued, but the curve flattened. Stool frequency stabilized at 3 to 4 per day, which is approximately my well-controlled baseline. Urgency mostly resolved. Blood appeared only occasionally, maybe twice in this entire two-week window.

No side effects from the peptide that I could attribute. Mood steady. Sleep steady.

The boring truth about a response like this is that after the initial relief of “something is happening,” you settle into a new normal and start wondering whether you’re just regressing to the mean. UC fluctuates. Flares resolve. This is the epistemological problem with n=1 observations, and there’s no way to think your way out of it without controlled data.

Weeks 7 and 8: Steady state

The week-8 labs: fecal calprotectin 198, CRP 3. Both within a range my gastroenterologist would call good control. Stool frequency 2 to 4 per day, mostly formed, blood rare.

By any standard symptom measure, I was in functional remission at 8 weeks. The calprotectin hadn’t normalized to under 100, which is what my gastroenterologist wants for evidence of full mucosal healing, but it was within striking distance.

To put those numbers in context: going from 612 to 198 on calprotectin over eight weeks while on stable mesalamine is a trajectory I hadn’t seen in my five years with this disease.

What this actually tells us (and what it doesn’t)

Let me be precise. For me, an 8-week course of compounded KPV added to standard mesalamine therapy was associated with significant clinical and biomarker improvement.

That sentence carries a lot of weight in the word “associated.” UC has natural fluctuation. Flares can resolve on standard treatment alone. The placebo effect of injecting yourself with something you believe might work is real and measurable. Without a controlled trial, clean attribution is impossible.

My genuinely opinionated take: the consistency of the response curve, the correlation between subjective symptom improvement and objective lab marker movement, and the timing all make me think this is more than coincidence. But I also know that every person who has ever improved on a supplement, a prayer, or a lucky charm has thought exactly the same thing. So I hold that opinion loosely.

What my gastroenterologist thinks

She’s appropriately skeptical. Her position: the symptom improvement and biomarker movement are real, the timing correlates with adding the peptide, and the safety profile of KPV in the limited published data appears reasonable. She’s not changing the mesalamine. She’s supportive of continuing the KPV protocol for another 8 weeks under her monitoring and Dr. Stein’s.

She also wants a colonoscopy at month 6 to assess mucosal healing. Lab markers and symptoms are useful proxies, but the scope is what determines true remission. Think of it like checking the foundation of a house rather than just looking at whether the walls seem straight.

Side effects at eight weeks

Eight weeks of twice-daily subcutaneous injections. No injection-site reactions beyond brief warmth. No systemic side effects. No detectable changes in CBC, CMP, lipid panel, or any other lab marker outside the inflammatory markers that improved.

The melanocortin pathway that KPV interacts with can theoretically produce skin pigmentation changes, similar to other melanocortin-active peptides. I haven’t noticed any pigmentation changes at 8 weeks. Both doctors are watching for this.

Cost breakdown

The 8-week protocol ran about $340 through FormBlends KPV, the compounded telehealth pharmacy fulfilling my prescription through a licensed 503A compounding pharmacy. Including Dr. Stein’s consults at intake and follow-up, total cost was roughly $640. For context, biologic therapy for UC (adalimumab, vedolizumab, etc.) can run $15,000 to $30,000 per year after insurance negotiation. The cost framing for me: if an adjunctive intervention reduces the chance of needing biologics later, $640 for an 8-week trial is an easy decision.

What happens next

Continue the KPV protocol at the same dose for another 8 weeks. Repeat fecal calprotectin and CRP at week 12 and week 16. Colonoscopy at month 6.

If the trajectory continues toward remission and the colonoscopy shows mucosal healing, the question becomes whether to maintain KPV indefinitely, cycle it, or use it only during flare periods. That conversation happens with both doctors when we have the imaging data.

If the trajectory reverses, I’ll write that up too.

See also: Balancing the Ledger: How Australian Students Master Modern University Requirements

Why document this mid-stream

Because the week-by-week shape of a response is the part that’s hardest to find. Most writeups compress months into a paragraph. What I would have wanted before starting was exactly this: a daily symptom log translated into plain language, with lab values attached, written by someone who doesn’t have an answer yet. One data point isn’t evidence. But the literature that barely exists for this peptide in humans needs more data points, not fewer.

Week 16 update with colonoscopy results will follow.

Not FDA-approved. KPV is prescribed off-label and prepared by licensed 503A compounding pharmacies for individual patients based on clinical judgment. This is personal experience under physician supervision, not medical advice.